Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 3
2015 2
2016 1
2017 2
2018 4
2019 1
2020 4
2021 4
2022 5
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Results by year
Filters applied: . Clear all
Page 1
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
van der Heijde D, Gensler LS, Maksymowych WP, Landewé R, Rudwaleit M, Bauer L, Kumke T, Kim M, Auteri SE, Hoepken B, Deodhar A. van der Heijde D, et al. Among authors: hoepken b. RMD Open. 2022 Mar;8(1):e002138. doi: 10.1136/rmdopen-2021-002138. RMD Open. 2022. PMID: 35296532 Free PMC article. Clinical Trial.
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
Robinson PC, Maksymowych WP, Gensler LS, Hall S, Rudwaleit M, Hoepken B, Bauer L, Kumke T, Kim M, de Peyrecave N, Deodhar A. Robinson PC, et al. Among authors: hoepken b. ACR Open Rheumatol. 2022 Sep;4(9):794-801. doi: 10.1002/acr2.11469. Epub 2022 Jun 22. ACR Open Rheumatol. 2022. PMID: 35733363 Free PMC article.
Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study.
Katsifis G, Theodoridou A, Bounas A, Georgiou P, Sfikakis P, Fragiadaki K, Dimitroulas T, Mole E, Bauer L, Kumke T, Hoepken B. Katsifis G, et al. Among authors: hoepken b. Mediterr J Rheumatol. 2022 Apr 15;33(Suppl 1):162-172. doi: 10.31138/mjr.33.1.162. eCollection 2022 Mar. Mediterr J Rheumatol. 2022. PMID: 36127922 Free PMC article.
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
Baraliakos X, Witte T, De Clerck L, Frediani B, Collantes-Estévez E, Katsifis G, VanLunen B, Kleine E, Hoepken B, Bauer L, Goodson N. Baraliakos X, et al. Among authors: hoepken b. Rheumatology (Oxford). 2021 Jan 5;60(1):113-124. doi: 10.1093/rheumatology/keaa181. Rheumatology (Oxford). 2021. PMID: 32584415 Free PMC article.
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Landewé RB, van der Heijde D, Dougados M, Baraliakos X, Van den Bosch FE, Gaffney K, Bauer L, Hoepken B, Davies OR, de Peyrecave N, Thomas K, Gensler LS. Landewé RB, et al. Among authors: hoepken b. Ann Rheum Dis. 2020 Jul;79(7):920-928. doi: 10.1136/annrheumdis-2019-216839. Epub 2020 May 7. Ann Rheum Dis. 2020. PMID: 32381562 Free PMC article. Clinical Trial.
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.
Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D. Deodhar A, et al. Among authors: hoepken b. Arthritis Rheumatol. 2019 Jul;71(7):1101-1111. doi: 10.1002/art.40866. Epub 2019 May 28. Arthritis Rheumatol. 2019. PMID: 30848558 Free PMC article. Clinical Trial.
25 results